Elevated expression of the leptin receptor ob‑R may contribute to inflammation in patients with ulcerative colitis

Tian,Yan‑Ming; Tian,Si‑Yu; Wang,Dong; Cui,Fang; Zhang,Xiang‑Jian; Zhang,Yi

doi:10.3892/mmr.2019.10720

Elevated expression of the leptin receptor ob‑R may contribute to inflammation in patients with ulcerative colitis

Authors:
- Yan‑Ming Tian
- Si‑Yu Tian
- Dong Wang
- Fang Cui
- Xiang‑Jian Zhang
- Yi Zhang
View Affiliations

Affiliations: Department of Physiology, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China, Department of Gastroenterology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Hebei Collaborative Innovation Center for Cardio‑Cerebrovascular Disease, Shijiazhuang, Hebei 050000, P.R. China
Published online on: October 1, 2019 https://doi.org/10.3892/mmr.2019.10720
Pages: 4706-4712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The effect of leptin on ulcerative colitis (UC) has been controversial. The present study aimed to investigate the role of leptin and its receptor ob‑R in UC and the underlying mechanism of this role. The level of serum leptin and the protein expression of the leptin receptor ob‑R in the colonic mucosa were determined in patients with UC. Experimental colitis was induced through intrarectal administration of 2,4,6‑trinitrobenzene sulfonic acid (TNBS) in leptin receptor‑deficient Zucker rats (LR‑D). The body weight, disease activity index, colon length, and macroscopic and histopathological appearance were evaluated. Furthermore, the myeloperoxidase (MPO) enzyme activity and cytokine levels in colon tissues were also determined. The expression of the signal transducer and activator of transcription 3 (STAT3), phosphorylated STAT3 (p‑STAT3), nuclear factor (NF)‑κB‑p65, and Ras homolog gene family member A (RhoA) proteins in colon tissues was assessed. The results revealed that the expression of the leptin receptor ob‑R was increased in the colonic mucosa but the serum leptin level was not altered in patients with UC compared with healthy volunteers. The severity of experimental colitis, represented by body weight loss, disease activity index, colon length, and macroscopic and histological changes, was ameliorated in LR‑D rats compared with the wild‑type (WT) rats. Moreover, the MPO activity; levels of cytokines including interleukin (IL)‑1β, IL‑6, and tumor necrosis factor‑α; and expression of p‑STAT3, NF‑κB, and RhoA proteins were reduced in colon tissues of LR‑D rats compared with WT rats. In conclusion, activation of the leptin receptor ob‑R is an important pathogenic mechanism of UC, and leptin receptor deficiency may provide resistance against TNBS‑induced colitis by inhibiting the NF‑κB and RhoA signaling pathways.

View Figures

View References

1	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, et al: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 390:2769–2778. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhou M, He J, Shen Y, Zhang C, Wang J and Chen Y: New frontiers in genetics, gut microbiota and immunity: A Rosetta stone for the pathogenesis of inflammatory bowel disease. Biomed Res Int. 2017:82016722017. View Article : Google Scholar : PubMed/NCBI
3	Coskun M, Vermeire S and Nielsen OH: Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 38:127–142. 2017. View Article : Google Scholar : PubMed/NCBI
4	Münzberg H and Morrison CD: Structure, production and signaling of leptin. Metabolism. 64:13–23. 2015. View Article : Google Scholar : PubMed/NCBI
5	Abella V, Scotece M, Conde J, Pino J, Gonzalez-Gay MA, Gómez-Reino JJ, Mera A, Lago F, Gómez R and Gualillo O: Leptin in the interplay of inflammation, metabolism and immune system disorders. Nat Rev Rheumatol. 13:100–109. 2017. View Article : Google Scholar : PubMed/NCBI
6	Singh UP, Singh NP, Guan H, Busbee B, Price RL, Taub DD, Mishra MK, Fayad R, Nagarkatti M and Nagarkatti PS: Leptin antagonist ameliorates chronic colitis in IL-10⁻/⁻ mice. Immunobiology. 218:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
7	Cakir B, Bozkurt A, Ercan F and Yeğen BC: The anti-inflammatory effect of leptin on experimental colitis: Involvement of endogenous glucocorticoids. Peptides. 25:95–104. 2004. View Article : Google Scholar : PubMed/NCBI
8	Bozkurt A, Cakir B, Ercan F and Yeğen BC: Anti-inflammatory effects of leptin and cholecystokinin on acetic acid-induced colitis in rats: Role of capsaicin-sensitive vagal afferent fibers. Regul Pept. 116:109–118. 2003. View Article : Google Scholar : PubMed/NCBI
9	Kahraman R, Calhan T, Sahin A, Ozdil K, Caliskan Z, Bireller ES and Cakmakoglu B: Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease? Ther Clin Risk Manag. 13:1295–1301. 2017. View Article : Google Scholar : PubMed/NCBI
10	Trejo-Vazquez F, Garza-Veloz I, Villela-Ramirez GA, Ortiz-Castro Y, Mauricio-Saucedo P, Cardenas-Vargas E, Diaz-Baez M, Cid-Baez MA, Castañeda-Miranda R, Ortiz-Rodriguez JM, et al: Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study. Exp Ther Med. 15:3336–3344. 2018.PubMed/NCBI
11	Ghomraoui FA, Alotaibi ST, Alharthi MA, Asiri SS, Almadi MA, Alharbi OR, Azzam NA, Aljebreen AM, Saeed M, Hajkhder B, et al: Plasma ghrelin and leptin in patients with inflammatory bowel disease and its association with nutritional status. Saudi J Gastroenterol. 23:199–205. 2017.PubMed/NCBI
12	Nikolaus S and Schreiber S: Diagnostics of inflammatory bowel disease. Gastroenterology. 133:1670–1689. 2007. View Article : Google Scholar : PubMed/NCBI
13	Lin H, Honglang L, Weifeng L, Junmin C, Jiantao Y and Junjing G: The mechanism of alopolysaccharide protecting ulceralive colitis. Biomed Pharmacother. 88:145–150. 2017. View Article : Google Scholar : PubMed/NCBI
14	Wang J, Chen H, Wang Y, Cai X, Zou M, Xu T, Wang M, Wang J and Xu D: Therapeutic efficacy of a mutant of keratinocyte growth factor-2 on trinitrobenzene sulfonic acid-induced rat model of Crohn's disease. Am J Transl Res. 8:530–543. 2016.PubMed/NCBI
15	Zhao HM, Wang Y, Huang XY, Huang MF, Xu R, Yue HY, Zhou BG, Huang HY, Sun QM and Liu DY: Astragalus polysaccharide attenuates rat experimental colitis by inducing regulatory T cells in intestinal Peyer's patches. World J Gastroenterol. 22:3175–3185. 2016. View Article : Google Scholar : PubMed/NCBI
16	Lu Y, Lin H, Zhang J, Wei J, Sun J and Han L: Sijunzi Decoction attenuates 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats and ameliorates TNBS-induced claudin-2 damage via NF-κB pathway in Caco2 cells. BMC Complement Altern Med. 17:352017. View Article : Google Scholar : PubMed/NCBI
17	Flatow EA, Komegae EN, Fonseca MT, Brito CF, Musteata FM, Antunes-Rodrigues J and Steiner AA: Elucidating the role of leptin in systemic inflammation: A study targeting physiological leptin levels in rats and their macrophages. Am J Physiol Regul Integr Comp Physiol. 313:R572–R82. 2017. View Article : Google Scholar : PubMed/NCBI
18	Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, et al: Guidelines for the management of inflammatory bowel disease in adults. Gut. 60:571–607. 2011. View Article : Google Scholar : PubMed/NCBI
19	Pan WW and Myers MG Jr: Leptin and the maintenance of elevated body weight. Nat Rev Neurosci. 19:95–105. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wang B, Chandrasekera PC and Pippin JJ: Leptin- and leptin receptor-deficient rodent models: Relevance for human type 2 diabetes. Curr Diabetes Rev. 10:131–145. 2014. View Article : Google Scholar : PubMed/NCBI
21	Paik J, Fierce Y, Treuting PM, Brabb T and Maggio-Price L: High-fat diet-induced obesity exacerbates inflammatory bowel disease in genetically susceptible Mdr1a-/- male mice. J Nutr. 143:1240–1247. 2013. View Article : Google Scholar : PubMed/NCBI
22	Sun SC: The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 17:545–58. 2017. View Article : Google Scholar : PubMed/NCBI
23	Fan Y, Mao R and Yang J: NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell. 4:176–185. 2013. View Article : Google Scholar : PubMed/NCBI
24	Hayden MS and Ghosh S: Regulation of NF-κB by TNF family cytokines. Semin Immunol. 26:253–266. 2014. View Article : Google Scholar : PubMed/NCBI
25	El-Salhy M and Umezawa K: Effects of AP-1 and NF-κB inhibitors on colonic endocrine cells in rats with TNBS-induced colitis. Mol Med Rep. 14:1515–1522. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lee C, Kim BG, Kim JH, Chun J, Im JP and Kim JS: Sodium butyrate inhibits the NF-kappa B signaling pathway and histone deacetylation, and attenuates experimental colitis in an IL-10 independent manner. Int Immunopharmacol. 51:47–56. 2017. View Article : Google Scholar : PubMed/NCBI
27	Segain JP, Raingeard de la Blétière D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, Pacaud P, Galmiche JP and Loirand G: Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: Evidence in Crohn's disease and experimental colitis. Gastroenterology. 124:1180–1187. 2003. View Article : Google Scholar : PubMed/NCBI
28	Zou Y, Ma L, Zhao Y, Zhang S, Zhou C and Cai Y: Inhibition of Rho kinase protects against colitis in mice by attenuating intestinal epithelial barrier dysfunction via MLC and the NF-κB pathway. Int J Mol Med. 41:430–438. 2018.PubMed/NCBI